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Since the introduction of biologics for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA),
ankylosing spondylitis (AS), and psoriasis (Pso) an increased risk of tuberculosis (TB) reactivation in patients
with latent tuberculosis infection (LTBI) has been recorded for anti-TNF agents, while a low or absent risk is
associated with the non-anti-TNF targeted biologics. To reduce this risk several recommendation sets have
been published over time, but in most of them the host-related risk, and the predisposing role to TB reactiva-
tion exerted by corticosteroids and by the traditional disease-modifying anti-rheumatic drugs has not been
adequately addressed. Moreover, the management of the underlying disease, and the timing of biologic
restarting in patients with TB occurrence have been rarely indicated. A multidisciplinary expert panel, the
Italianmultidisciplinary task force for screening of tuberculosis before and during biologic therapy (SAFEBIO),
was constituted, and through a review of the literature, an evidence-based guidance for LTBI detection, iden-
tiﬁcation of the individualized level of risk of TB reactivation, and practical management of patients with TB
occurrence was formulated. The literature review conﬁrmed a higher TB risk associated with monoclonal
anti-TNF agents, a low risk for soluble receptor etanercept, and a low or absent risk for non-anti-TNF targeted
biologics. Considering the TB reactivation risk associated with host demographic and clinical features, and
previous or current non-biologic therapies, a low, intermediate, or high TB reactivation risk in the single
patient was identiﬁed, thus driving the safest biologic choice. Moreover, based on the underlying disease
activity measurement and the different TB risk associated with non-biologic and biologic therapies, practical
indications for the treatment of RA, PsA, AS, and Pso in patients with TB occurrence, as well as the safest timing
of biologic restarting, were provided.
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1. Introduction
Over the last 15 years biologic drugs have ensured relevant advan-
tages in rheumatology and dermatology for the treatment of rheuma-
toid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis
(PsA), and psoriasis (Pso). To date, several agents with pharmacological
activity targeted on different levels of immune response are available in
clinical practice, including interleukin-6 inhibitor tocilizumab (TCZ),
anti-CD20 rituximab (RTX), anti-interleukin-1 anakinra (ANK), anti-
CD28 abatacept (ABA), anti-IL12-23 ustekinumab (UTK), and anti-
tumor necrosis factor alpha agents (anti-TNFα) including adalimumab
(ADA), etanercept (ETN), inﬂiximab (IFX), golimumab (GOL), and
certolizumab (CTP).
However, data from clinical trials and from real-life clinical practice
have shown that currently used biologics, namely the anti-TNFα and
to a lesser extent the non-anti-TNFα targeted agents, may constitute a
risk factor for tuberculosis (TB) reactivation in subjects with latent TB
infection (LTBI) [1,2]. Hence, LTBI screening and prevention of active
TB represent a current worldwide challenge for biologic prescribers.
To reduce the risk of TB reactivation several sets of recommendations
and guidelines have been proposed, but none of themmay be appropri-
ate for the single country due to the different social and economic con-
ditions and the variable prevalence of TB [3]. The majority of
recommendations/guidelines have been prompted for patients to be
treated with the oldest anti-TNFα, namely IFX, ETN and ADA, while no
policy document is available for the more recently marketed biologics
such as GOL, CTP, TCZ, RTX, ABA, and UTK.
In addition, most of the current recommendations raise some con-
cerns because they do not take in account the speciﬁc risk related to
the host and to the previous or current treatments, and only two sets
have been formulated through a multidisciplinary approach [4,5]. Fur-
thermore, although biologics are loaded by a different TB risk, none of
the recommendations provide indications for choosing the proper bio-
logic treatment in function of the speciﬁc risk associated with the single
patient. Finally, details concerning the management of the underlying
rheumatic disease or Pso in case of active TB occurrence have been rare-
ly indicated [6].
2. Objective
To provide an evidence-based algorithm for the detection of LTBI
and prevention of TB reactivation, to examine the clinical variables, in-
cluding the host-related, the traditional disease modifying anti-
rheumatic drug (DMARD)-related, and the single biologic agent-
related TB risk, that may inﬂuence the therapeutic choice in LTBI posi-
tive patients with RA, PsA, AS, and Pso requiring biologic therapy, and
to suggest practical indications for the management of the patients
with active TB complicating the clinical disease course.
3. Methods
3.1. SAFEBIO expert panel purpose
A multidisciplinary expert panel, the Italian multidisciplinary task
force for screening of tuberculosis before and during biologic therapy
(SAFEBIO), including specialists in rheumatology (FC, CN, LN, FI), mi-
crobiology (GD), radiology (GG), pneumology (ASZ), immunology
(AM), dermatology (FP), epidemiology (MC), and infectious diseases
(DG), was constituted to perform a systematic literature review on
the existing recommendations for LTBI screening before biologic
starting and overtime follow-up, the TB risk related to different bio-
logics, the host-related risk, the previous therapy-related risk, and to
formulate evidence-based practical guidelines for the management
of LTBI positive patients with inﬂammatory rheumatic disorders and
Pso.
3.2. Literature search
The literature reviewwasmade using PubMed database to identify
English-language articles related to the previously mentioned topics.
Regarding the TB risk associated with the speciﬁc biologic agent, all
published clinical trials, data from post-marketing surveillance, and
from national registries of currently used biologics for the treatment
of RA, AS, and PsA, and Pso were reviewed to identify all cases of TB
complicating the underlying rheumatic or dermatologic disease
course. Data were extracted from phase III randomized controlled tri-
als (RCTs), their open-label extension phase studies, and from open-
label, prospective studies of at least 12-week duration focused on
the efﬁcacy and safety of each drug. As an additional selection criteri-
on, we included only the studies published after October 2001, when
the recommendations for LTBI detection and TB reactivation preven-
tion where introduced. In addition, available data from biologic na-
tional registries, national healthcare databases, and post-marketing
surveillance surveys were included. Reviews and meta-analyses
were excluded.
The following drugs were investigated: IFX, ETN, ADA, GOL, CTP,
RTX, TCZ, ANK, ABA, and UTK. The research was performed by crossing
the single drug name with the following key terms: TB, infections,
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comorbidities, safety, registry, guidelines, and recommendations. For
each biologic were recorded the number of publications, the type of
trial, the number of enrolled patients, the number of TB cases and,
when possible, the setting where TB occurred. Moreover, the evidence
on LTBI detection, TB reactivation prophylaxis, host-related risk, the
risk associated with the underlying disease and with previous or con-
comitant non-biologic therapies was reviewed.
The literature review was extended to December 31, 2014.
4. Results
4.1. SAFEBIO evidence-based guidance for LTBI screening procedures and
active TB prophylaxis
LTBI screening procedures are mandatory before biologic starting. A
full clinical history and physical examination should be part of the initial
assessment. This should include details of ethnicity, country of birth,
history of recent exposure to TB, previous active TB and treatment com-
pletion, together with any additional risk such as drug or alcohol abuse
[7]. Fig. 1 shows the SAFEBIO recommendations in BCG-unvaccinated
and -vaccinated subjects. These recommendations have been devel-
oped on the basis of current evidence with respect to the sensitivity
and speciﬁcity of tuberculin skin test (TST), interferon gamma release
assay (IGRA), and chest radiograph used for LTBI screening and TB-
preventive therapy [8–10].
The panel recommends the use of the IGRA over the TST in patients
who had previously received a BCG vaccination, due to the high false
positive test rates for TST [11,12]. Due to the discrepancies between
TST and IGRA results [13,14], and the recent data on the better perfor-
mance of combined TST and IGRAs in the detection of LTBI [15], in
those that are not BCG-vaccinated, the panel recommends combined
use of TST and IGRA as the initial tests in all patients before starting bi-
ologic agents. Since TST may increase IGRA results [16], IGRA determi-
nation should precede TST execution.
RA, PsA, AS and Pso patients with a positive TST (≥5 mm in BCG-
unvaccinated) or IGRA (QFT-GIT ≥ 0.35 UI/ml; T-SPOTB when at least
one of the antigens has ≥6 spots) should have a chest radiograph and,
if suggestive of active TB, a subsequent sputum examination to evaluate
the presence ofMycobacterium tuberculosis.
Patients with RA, PsA, AS and Pso with a negative screening TST
or IGRA may not need further evaluation in the absence of risk
factors and/or absence of clinical suspicion for TB in low TB risk
countries.
The panel recommends annual testing for LTBI in RA, PsA, AS and Pso
patients with a negative screening TST or IGRA at baseline if they live,
travel, or work in situationswhere TB exposure is likely while they con-
tinue treatment with biologic agents.
After the screening, if the patient results with active TB, the panel
recommends appropriate anti-TB treatment and consideration of refer-
ral to a specialist. Oral andwritten information (education) on TB infec-
tion and disease should be provided to the patient.
For those deﬁned as LTBI, treatment with biologic agents can be ini-
tiated or resumed after 1month of LTBI treatmentwith anti-TBmedica-
tions (INH for 9 months, or INH + RFP for 3 months or RFP for 4
months) and after completion of the treatment of active TB, as applica-
ble [17,18]. LTBI patients scored positive to TST or IGRA at baseline can
remain positive to these tests even after successful TB preventive thera-
py [19]. These patients needmonitoring for clinical signs and symptoms
of active TB, since repeating TST or IGRAwill not help in the diagnosis of
TB reactivation [8].
Fig. 1. SAFEBIO recommendations for LTBI detection and active TB prevention in RA patients before biologic therapy starting.
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4.2. Evidence on host-related TB risk
In 2005, the Center for Disease Control and Prevention, Atlanta, indi-
cated the persons who are at highest risk of TB infection and those at
high risk of progression from LTBI to active TB, including people living
in close contact with persons with suspected or active TB, born in high
TB-risk countries, travelers who do frequent and prolonged visits in
areaswith a high prevalence of active TB, peoplewhowork in close con-
tact with subjects at increased risk of active TB such as those medically
underserved, low-income populations, drug or alcohol abusers, and in-
fants, children, and adolescents exposed to adults at high TB risk [7].
After screening, those deﬁned as LTBI, may have an increased risk of
TB reactivation based on age, socioeconomic status, lifestyle, malnutri-
tion, immune-suppression conditions and comorbidities [20]. In addi-
tion, the underlying autoimmune disease itself is associated with a
higher TB risk, ranging from 2.0 to 8.9 in RA patients not receiving bio-
logic therapies [21,22], and similar results were also reported in PsA and
Pso [23,24]. Table 1 reports the host-related TB risk featureswith indica-
tion of the relative risk value.
4.3. Evidence on previous or concomitant therapy-related risk
As recommended [25], the ﬁrst line therapy for patients with RA and
PsA is based on the use of corticosteroids (CS) and traditional disease
modifying anti-rheumatic drugs (DMARDs) including methotrexate
(MTX), hydroxychloroquine (HCQ), leﬂunomide (LEF), sulphasalazine
(SSZ), azathioprine (AZA), and cyclosporine A (CsA). This approach is
also valid for Pso even if the DMARDs prevalently used are MTX and
CsA [26], while traditional DMARDs are not recommended for the treat-
ment of AS [27]. It has long been recognized that in patients with LTBI a
prolonged CS therapy, or prednisone doses of 15 mg/day, or equivalent,
given for 1month ormore predispose to TB reactivation [28]. In a recent
British study a 3-fold increase of active TB cases in patients taking a dose
of prednisolone b7.5 mg/day has been reported [29]. Similarly, an ad-
justed relative risk (RR) of 2.4 was found in a large cohort of RA patients
receiving CS in Canada [23]. In the same report the traditional DMARD-
related TB riskwas assessed. The highest risk resulted for LEF (RR: 11.7),
almost equal risk for MTX and CsA (RR: 3.4 and 3.8, respectively), while
no increased risk was registered for HCQ, SSZ, and AZA [23]. Table 1 re-
ports the available data of traditional DMARD-related risk of TB
reactivation.
4.4. Evidence on single biologic-related risk and individualized biologic
choice
As previously reported [30], data from RCTs, national registries [31],
and post-marketing surveillance of biologics report a 2–6 fold higher
rate of TB reactivation in patients receiving anti-TNF agents, with
some differences among the speciﬁc drug. Indeed, the risk resulted
higher for monoclonal antibody anti-TNF ADA and IFX compared with
ETN, while no conclusive data were available for GOL and CTP due to
their recent introduction in the market. Since in the above quoted re-
view the literature analysis was limited toMay 31st, 2013, we extended
the search to December 31st, 2014. Overall, 3 newTB caseswere record-
ed in ADA trials [32–34], 1 case in IFX, CTP, and GOL trials respectively
[35–39], while no TB cases were observed in ETN trials, thus conﬁrming
the higher TB risk in monoclonal antibody anti-TNF-exposed patients
compared to those receiving ETN.
This concept seems to be reinforced by two recent studies of
biosimilar inﬂiximab. In the Planetra study [40], a RCT on 606 patients
with RA where CT-P13 (biosimilar inﬂiximab) efﬁcacy and safety was
compared to the originator IFX, 3 cases of active TB were recorded in
CT-P13 treatment arm, and in the Planetas study, conducted on 229 pa-
tients with AS, 2 cases of TB were observed in the CT-P13 and 1 case in
the originator IFX arms, respectively [41]. The limited data on biosimilar
inﬂiximab-related TB risk do not allow drawing of deﬁnitive conclusion,
and this concern needs to be better addressed in large clinical series
from real-life practice [42].
Of note, the combined use of anti-TNF agents and traditional
DMARDs exposes to a higher risk of TB reactivation in subjects with
LTBI compared to patients treated with anti-TNF monotherapy [43].
As recorded by the national registries of biologics and post-
marketing surveillances, data from real-life practice further support
the higher risk of TB reactivation associated with monoclonal antibody
anti-TNF compared to soluble receptor, with a pooledmedian incidence
rate/100,000/year of 83 cases for ETN, 203 for ADA, and 268 for IFX [30].
Similar data are not available for the recently marketed GOL and CTP.
Relative to non-anti-TNF targeted biologics, data of RTX, as expected
due to its action targeted on B-lymphocytes, showno TB cases occurring
in thousands of RA patients treated with this biologic [44,45]. Based on
this evidence, recently the Rituximab Consensus Expert Committee sug-
gested as unnecessary the screening procedures for LTBI before RTX
therapy starting [46]. An absent or low TB risk has been recorded in pa-
tients treatedwith ABA, TCZ, and UTK [44], and the low or absent risk of
TB reactivation in patients receiving ANK has been underlined in a re-
cent review [47].
With respect to our previous review [44], the literature update con-
ﬁrms no increased risk of TB reactivation in patients receiving TCZ
[48–53], ABA [33,54–56], and UTK [57–59].
4.5. SAFEBIO guidance for biologic starting in subjects requiring TB
prophylaxis
There is no clear evidence in the literature concerning the optimal
interval between the beginning of the preventive therapy for TB reacti-
vation and biologic therapy starting. Experimental data have shown
that 2-month INH therapy prevents the reactivation of LTBI and reduces
the bacterial load in Mtb-infected monkeys treated with ADA [60]. In
the absence of a similar evidence in humans, a lag time of 4 weeks be-
tween INH initiation and anti-TNF starting is considered safe by most
experts and the majority of the international recommendations [3].
Data from the Spanish registry BIOBADASER seem to support the
Table 1
Host-and traditional DMARD-related TB risk reactivation.
Host-related Traditional DMARD-related
Demographic characteristic and
comorbidity
Estimated
RR
Drug Estimated
RR
Age b50 years 2 Corticosteroids 2.4
Family history of TB 2.38 Methotrexate 3.4
Recent TB infection (b2 years) 15 Leﬂunomide 11.7
Former TB disease 2.69
Exposure to active TB subjects 10.1 Cyclosporine 3.8
Cigarette smoker 2 Other (sulphasalazine,
azathioprine,
hydroxychloroquine)
1.6
Alcohol abuse 1.84
Drug abuse 2.83
Malnutrition, low body weight
(BMI ≤ 20)
2
Pso/PsA [24] 3.1
Diabetes 3.11
RA [21] 3.68
AS [25] 3.9
Silicosis 30
Severe kidney disease 25
Abnormal chest x-ray—with
upper lobe ﬁbronodular
disease typical of healed TB
infection
19
Except where otherwise indicated, data are quoted from the reference number [20].
Abbreviations. DMARD: disease modifying anti-rheumatic drug; RR: relative risk; TB: tu-
berculosis; Pso: psoriasis; PsA: psoriatic arthritis; RA: rheumatoid arthritis; AS: ankylosing
spondylitis.
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above mentioned recommendations showing a signiﬁcant reduction of
active TB cases in patients receiving anti-TNF therapy after 1 month
from the initiation of the preventive therapy for TB reactivation [61].
As reported in Table 1, several conditions constitute major risk fac-
tors for TB reactivation, but in the case of patients with inﬂammatory
rheumatic disorders or Pso, the underlying autoimmune disease itself
increases the risk of TB reactivation. In addition, patients with RA, PsA,
and Pso who require biologic therapy have a more severe disease and
are usually treated with CS and traditional DMARDs that contribute to
increase the risk. This therapeutic background is usually absent in AS,
therefore these patients should be evaluated only for the host-related
risk factors.
In the absence of validated risk score to be applied to the single pa-
tient, it may be reasonable to stratify the patients in function of the ad-
junctive risk factors and of the single biologic-related risk. As shown in
Table 1, the RR values of risk factors have a bimodal distribution,
below and above 10. Therefore, the host-related risk factors with an as-
sociated RR N 10were arbitrarily categorized asmajor, and those below
this cut-off asminor. In the last category we included the risk factors as-
sociated with the socio-economic status, traveling in high-risk country,
and working in increased TB risk settings. In addition, patients present-
ingwith two or moreminor risk factors were considered as at high risk.
In analogy with the validated RABBIT infection risk score [62], LTBI
patientswith RA, PsA, AS, and Psomaybe stratiﬁed in low, intermediate,
and high risk as reported in Table 2. On this basis, patients at low risk
may be treated with any biologic agent, RA patients with intermediate
risk with non-anti-TNF targeted agents or with low TB risk ETN, while
ETN and UTK are indicated for PsA. (See Table 2).
Concerning patients at high risk, ABA, TCZ, and ANK represent the
drug of choice for RA therapy. Regarding RA therapy, RTX is not included
in Table 2 because in Italy the drug has been licensed as second-line
therapy.
Since only anti-TNF drugs are licensed for the treatment of AS, in pa-
tients at intermediate risk ETN is indicated, while in those at high risk, in
view of some evidence of efﬁcacy, bisphosphonates [63,64]may be tried
before starting ETN.
In Pso patients at low risk all biologics may be employed, otherwise
the drugs of choice are ETN or UTK in those at intermediate risk, and
only UTK in high-risk subjects.
4.6. SAFEBIO guidance for the management of RA, AS, PsA and Pso in the
case of active TB occurrence
Biologic therapy withdrawn ismandatory in the case of active TB di-
agnosis. Patients with inﬂammatory rheumatic disorders may be treat-
ed with analgesics, non-steroidal anti-inﬂammatory drugs (NSAIDs). In
Table 2
SAFEBIO guidance for biologic choice in patients with RA, PsA, AS, and Pso stratiﬁed in different categories of TB risk.
Disease Risk factors Risk category First biologic choice
Rheumatoid arthritis DMARD + CS + no host-related RF Low Any
DMARD + CS + 1 minor host-related RF Intermediate ABA, TCZ, ANK, ETN
DMARD + CS + 2 or N2 minor host-related RFs High ABA, TCZ, ANK
DMARD + CS + 1 major host-related RF
Psoriatic arthritis DMARD + CS + no host-related RF Low Any
DMARD + CS + 1 minor host-related RF Intermediate ETN, UTK
DMARD + CS + ≥2 minor host-related RFs High UTK
DMARD + CS + 1 major host-related RF
Ankylosing spondylitis No host-related RF Low Any anti-TNF
≤2 minor host-related RFs Intermediate ETN
N2 minor host-related RFs
1 major host-related RF
High Try bisphosphonates
ETN (tight control for TB reactivation)
Psoriasis DMARD + CS + no host-related RF Low Any
DMARD + CS + 1 minor host-related RF Intermediate ETN, UTK
DMARD + CS + ≥2 minor host-related RFs High UTK
DMARD + CS + 1 major host-related RF
Abbreviations. RF= risk factor; DMARD=diseasemodifying anti-rheumatic drug; CS= corticosteroids; ABA= abatacept; TCZ= tocilizumab; ANK= anakinra; ETN= etanercept; UTK
= ustekinumab.
Table 3
Panel guidance for the management of RA, PsA, AS and Pso in patients with active TB complicating the disease course.
Disease Disease
activity
Treatmenta
Rheumatoid arthritis Low (DAS28: b3.2) NSAIDs, analgesics, ICLR, SSZ.
Restart biologics after 6 months of therapy for active TB.
Moderate (DAS28: 3.3–5.0) After 2-month of therapy for active TB, it is possible to use CS (as low as possible dose) + MTX or CsA.
Restart biologics after 6 months of therapy for active TB.
High (DAS28: N5.1) After 2-month therapy for active TB it is possible to restart a low risk biologic: ANK, TCZ, RTX, and ABA
for RA.
Peripheral psoriatic arthritis Low (DAS28: b3.2) NSAIDs, analgesics, SSZ.
Restart biologics after 6 months of therapy for active TB.
Moderate (DAS28: 3.3–5.0) After 2-month therapy for active TB, it is possible to use CS (as low as possible dose) + MTX or CsA.
Restart biologics after 6 months of therapy for active TB.
High (DAS28: N5.1) After 2-month therapy for active TB it is possible to restart a low risk biologic, preferably UTK and ETN as
second choice
Axial psoriatic arthritis
Ankylosing spondylitis
Inactive (ASDAS: b1.3) NSAIDs on demand.
Moderate (ASDAS: 1.4–2.0) NSAIDs at full doses.
High (ASDAS: N2.1– b 3.5) After 2-month therapy for active TB, if no response to NSAIDs, try bisphosphonates or restart anti-TNF,
preferably ETN.
Psoriasis Low (PASI: b5) Topical therapy.
Moderate (PASI: 5.1–10.0) Topical therapy and/or phototherapy.
High (PASI: N10.0) After 2-month therapy for active TB restart a low risk biologic, preferably UTK, or ETN as second choice.
a When necessary, local CS inﬁltrative therapy is allowed in patients with RA, PsA, and AS.
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more severe cases, low-risk DMARDs such as hydroxychloroquine
(HCQ) and sulphasalazine (SSZ) in RA and only sulphasalazine in AS
and PsA (due to inefﬁcacy of HCQ in these patients) can be used. Pa-
tients with Pso should be treated with local therapy and phototherapy.
In collaboration with the local infectious disease specialists or
pneumologists, patientswith reactivated TB should undergo tomonthly
evaluation for toxicity of TB drugs and rigorously observe the interna-
tional schemes for the clinical, radiological and microbiological TB
follow-up (months 2 and 6) [65].
However, to date there are no guidelines/recommendations stating
the correct management of the underlying rheumatic disease or Pso in
patients treated for active TB and when to restart the biologics in case
of severe diseaseﬂare. As shown in Table 3, according to previous report
[66], SAFEBIO expert panel suggests modulating the treatment based on
the disease activity as measured by DAS28 for RA and PsA [67], ASDAS
for AS [68], and PASI for Pso [69].
According to other reports [70,71], biologics may be restarted after
at least 6 months of active TB treatment which usually corresponds to
treatment completion. In the case of severeﬂarewith high disease activ-
ity low risk biologicsmay be restarted after the 2-month induction ther-
apy for TB.
4.7. SAFEBIO guidance for patient monitoring after TB therapy withdrawal
After the successful completion of TB therapy, patient education on
symptoms and signs of active TB through given oral andwritten instruc-
tions is recommended. Moreover patients should be referred to the
infectologist/pneumologist twice a year over the ﬁrst 2 years from TB
therapy completion. Patients should be also informed to contact an
infectivologist/pneumologist in case of TB signs/symptoms recurrence.
5. Conclusion
Biologics are characterized by different molecular structure and
pharmacologic target with relevant differentiation concerning the risk
of TB reactivation. Hence, clinicians should properly screen for LTBI
the patients with RA, PsA, As, and Pso who are candidates for biologic
therapy, and LTBI subjects need to be properly assessed for different
risk factors related to the host demographic and comorbidity features
and to the previous or current immunosuppressive therapies.
Based on the literature data patients may be divided in different risk
categories that may drive the appropriate biologic choice to ensure the
safest treatment. The SAFEBIO expert panel guidance may represent a
useful instrument for the management of LTBI in patients with autoim-
mune diseases and for the treatment of the underlying disease in case of
TB reactivation.
6. Take-home messages
• The risk associated with the demographic characteristics, the pres-
ence of comorbidities, the previous or current non-biologic drug ex-
posure, and the different predisposing roles of biologics should be
evaluated in patients with RA, PsA, AS, and Pso who are positive for
LTBI and require biologic therapies.
• Through an evidence-based approach, LTBI positive patients may be
categorized as at low, intermediate, and high risk of TB reactivation,
with consequent reﬂexes on the choice of the safest treatment.
• The underlying disease treatment in patients with Tb occurrence
should be guided by the disease activity assessment.
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